Japan’s largest drugmaker Takeda says it aims to seek marketing authorisation for its TAK-755 enzy...
Read moreBe the first to receive exclusive content on the latest from the pharmaceutical and market access sector.
Remap Consulting have significant experience working with pharmaceutical and biotech companies in helping them navigate global market access.
Get in touchUS Most Favoured Nation (MFN) policy continues to evolve.
Join our complimentary 30-minute Office Hours session to explore the latest developments and what they could mean for pricing, launch sequencing and global strategy.
Hosted by Paul Craddy & Nicole Lodowski
